Fidaxomicin - CAS 873857-62-6
Catalog number:
B0084-454376
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C52H74CL2O18
Molecular Weight:
1058.06
COA:
Certificate of Analysis-Fidaxomicin 873857-62-6 B14Q0315  
Targets:
Antibacterial
Description:
Fidaxomicin(OPT-80; PAR-101) is a new class of narrow spectrum macrocyclic antibiotic drug; selective eradication of pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-454376 50 mg $298 In stock
B0084-454376 2 g $490 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥ 98.0%
Appearance:
White powder
Synonyms:
FidaxoMicin; 3-(((6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-b-D-mannopyranosyl)oxy)-methyl)-12(R)-[(6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-b-D-lyxo-hexopyranosyl)oxy]-11(S)-ethyl-8(S)-hydroxy-18(S)-(1(R)-hydroxyethyl)-9,13,15-trimethyloxacyclooctadeca-3,5,9,13,15-pentaene-2-one; OPT-80; PAR-101; R-Tiacumicin B; FidaxoMicin(LipiarMycin); ClostoMicin B1, LipiarMycin A3, TiacuMicin B, OPT 80; Oxacyclooctadeca-3,5,9,13,15-pentaen-2-one, 3-[[[6-deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-β-D-mannopyranosyl]oxy]methyl]-12-[[6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-β-D-lyxo-hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-, (3E,5E,8S,9E,11S,12R,13E,15E,18S)-
Solubility:
Sparingly soluble in methanol; slightly soluble in water and insoluble in chloroform.
Storage:
-20°C
MSDS:
Inquire
Application:
One of the first narrow spectrum macrocyclic antibiotic; FDA approved on May 27, 2011
Quality Standard:
In-house Standard
Quantity:
Milligrams-Grams
InChIKey:
ZVGNESXIJDCBKN-LGPUCNCQSA-N
InChI:
1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22-,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1
Canonical SMILES:
CCC1C=C(C(CC=CC=C(C(=O)OC(CC=C(C=C(C1OC2C(C(C(C(O2)(C)C)OC(=O)C(C)C)O)O)C)C)C(C)O)COC3C(C(C(C(O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)C
1.Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain
C. Rubio-Terrés & J. Cobo Reinoso & S. Grau Cerrato & J. Mensa Pueyo. Eur J Clin Microbiol Infect Dis (2015) 34:2213–2223
Fidaxomicin is an antibiotic that belongs to the class of the macrocyclics and is indicated for the treatment of CDI. In clinical trials, fidaxomicin, when compared to vancomycin, was non-inferior for the clinical cure of patients with CDI and superior for the reduction of recurrence rates, with a greater sustained response after 30 days. Of the patients included in the clinical trials, additional subgroup analyses were performed in patient subgroups with a higher risk of recurrence than the overall CDI population. These subgroups were patients with cancer [odds ratio (OR)=0.37; p=0.018], patients treated with concomitant antibiotic treatment (OR=0.492; p=0.0499) and patients with renal impairment (OR=0.487; p<0.001). Moreover, in these patients, CDI had a greater impact on morbidity and mortality and increased hospital costs compared to the overall CDI patient group.
2.Clostridium difficile: Deleterious Impact on Hematopoietic Stem Cell Transplantation
Alejandro Callejas-Díaz & Juan C. Gea-Banacloche. Curr Hematol Malig Rep (2014) 9:85–90
Newer treatment modalities include fidaxomicin (a nonabsorbable antibiotic with narrow spectrum of action that has shown to be noninferior to vancomycin) and fecal transplantation, a modality that attempts to restore the intestinal flora and has shown to be superior to oral vancomycin in a randomized controlled trial. The 2013 European guidelines state there is not enough evidence to make a recommendation regarding the use of fidaxomicin. A retrospective single-center study of the use of fidaxomicin in transplant (mainly solid organ) recipients did not find significant differences in outcome among the fifteen patients (including one HSCT recipient) who received fidaxomicin and the 44 who received conventional treatment. The authors emphasize no VRE colonization was observed in the fidaxomicin recipients, although this was not statistically significant. A subgroup analysis of the fidaxomicin trials focusing in cancer patients suggests it may be superior to vancomycin in this population, but by its nature it cannot be considered other than hypothesis-generating (no HSCT recipients seem to have been included). The first report of successful use of fecal transplantation in an HSCT recipient with severe CDI refractory to medical therapy CDI was published in 2012. The patient developed CDI almost a year after HSCT, following chemotherapy for a relapse of the acute lymphoblastic leukemia that had been the indication for transplant, and over the course of three weeks failed treatment with metronidazole, vancomycin, intravenous immunoglobulin, fidaxomicin, rifaximin and tigecycline. She responded promptly to a fecal transplant from her husband, instilled in the upper jejunum by a naso-jejunal tube.
3.Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures
Jane A. Cecil. Curr Infect Dis Rep (2012) 14:612–619
In May 2011, fidaxomicin became the second drug to be approved by the FDA for treatment of CDI in adults, with a recommended dose of 200 mg twice daily. Fidaxomicin has several potential advantages in that it is associated with minimal systemic absorption, it has a narrow spectrum of activity with less effect on the normal colonic flora compared to other agents with an associated lower risk of selecting for resistant pathogens, and it is a bactericidal antibiotic unrelated to antibiotics used for systemic infections. The FDA’s approval of fidaxomicin was based on a the results of a multicenter, double-blind, randomized, parallel-group trial in which 629 patients with CDI were randomized to receive either fidaxomicin (200 mg by mouth every 12 hours) or oral vancomycin (125 mg every 6 hours) for 10 days. Patients were evaluated for clinical cure and for recurrence within 4 weeks of completing treatment. The rates of clinical cure with fidaxomicin were not inferior to those with vancomycin in both the modified intention-to-treat analysis (88.2 % for fidaxomicin, 85 % with vancomycin) and the per-protocol analysis (92.1 % with fidaxomicin, 89.8 % with vancomycin). Significantly fewer patients in the fidaxomicin group experienced a recurrence of CDI relative to the vancomycin group in both analyses (15.4 % vs. 25.3 %, P00.005, in the modified intention-to-treat analysis). Lower rates of recurrence were not seen in patients infected with the NAP-1 strain, however, and there was a similar loss of efficacy for both drugs in these patients. In a subgroup analysis of 128 patients in the per-protocol population that had had a recent episode of CDI prior to the diagnosis of CDI at study enrollment, initial response to therapy was similar with both drugs (>90 % cure). However, a second recurrence occurred within 4 weeks in 35.5 % of patients treated with vancomycin and in 19.7 % of patients treated with fidaxomicin (P0 0.045). This is the only study to date evaluating the efficacy of fidaxomicin for the treatment of recurrent disease. Fidaxomicin is expensive, and its place in treatment algorithms for CDI, both initial and recurrent, remains to be fully determined. Additional studies of the efficacy of fidaxomicin in treating patients with multiple recurrences are needed and currently there are no published trials to support its use in this context.
4.Clostridium difficile Infection: Current and Emerging Therapeutics
Angie M. Jarrad, Mark A. T. Blaskovich, Dena Lyras, Matthew A. Cooper. Curr Treat Options Infect Dis (2015) 7:317–334
CDI can be difficult to treat with antibiotics, since recurrent infection is common. C. difficile forms dormant, persistent spores that are difficult to eradicate from hospitals and contribute to transmission, reinfection, and disease relapse. Metronidazole and vancomycin do not prevent spore formation or spore viability whereas fidaxomicin partially inhibits spore formation, which may contribute to reduced relapse rates in patients treated with the latter antibiotic. Antibiotic treatment also causes further damage to the gut microbiome, increasing patient susceptibility to recurrent disease. Vancomycin and metronidazole are broad spectrum antibiotics that can kill beneficial intestinal microbiota, while fidaxomicin has a narrower range, which probably allows the natural microbiota to be somewhat restored and therefore reduces CDI recurrence. Recurrent infection is increasingly being treated with microbiota restorative approaches, with fecal transplant as the most common approach. Emerging antimicrobial treatment options are focused on reducing recurrence by the development of C. difficile selective antimicrobials that are sporicidal and/or effective at inhibiting spore formation or outgrowth. Antimicrobial agents that are orally delivered but not absorbed well in the gastrointestinal tract are also preferred as this results in high concentrations in the colon and limits systemic side effects.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Antibacterial Products


CAS 13009-99-9 Mafenide Acetate

Mafenide Acetate
(CAS: 13009-99-9)

Mafenide is a bacteriostatic antibiotic with a broad activity against Gram positive, Gram negative bacteria and Clostridia. Mafenide acetate penetrates eschar a...

CAS 37661-08-8 Bacampicillin Hydrochloride

Bacampicillin Hydrochloride
(CAS: 37661-08-8)

Bacampicillin is a prodrug of ampicillin, a broad-spectrum aminopenicillin antibiotic with bactericidal activity.

CAS 25389-94-0 Kanamycin sulfate

Kanamycin sulfate
(CAS: 25389-94-0)

Antibiotic. Inhibits translocation during protein biosynthesis

Oritavancin diphosphate
(CAS: 192564-14-0)

Oritavancin, also known as LY333328, is a novel semisynthetic glycopeptide antibiotics.Oritavancin possesses potent and rapid bactericidal activity in vitro aga...

CAS 5321-32-4 Hetacillin potassium

Hetacillin potassium
(CAS: 5321-32-4)

Hetacillin potassium is a penicillin beta-lactam antibiotic reatment for use against a wide range of common Gram-positive and Gram-negative bacteria.

CAS 132-92-3 Meticillin sodium salt

Meticillin sodium salt
(CAS: 132-92-3)

The sodium salt of Meticillin, a β-lactam antibiotic, could be obtained through semi-synthetic and used as an antibacterial agent especially against Gram-positi...

CAS 35523-45-6 Fludalanine

Fludalanine
(CAS: 35523-45-6)

Fludalanine, an analogue of D-alanine that irreversibly inactivates the racemase, inhibits the synthetase.

CAS 53179-09-2 Sisomicin sulfate

Sisomicin sulfate
(CAS: 53179-09-2)

Sisomicin sulfate is an aminoglycoside antibiotic displaying a broad spectrum antibiotic activity.

CAS 15686-71-2 Cephalexin

Cephalexin
(CAS: 15686-71-2)

Cephalexin increases the activity of superficial mucous cells and orifice mucous cells of gastric glands, and inhibits the activity of cervix mucous cells.

CAS 127-56-0 Sulfacetamide Sodium

Sulfacetamide Sodium
(CAS: 127-56-0)

Sulfacetamide Sodium is an anti-biotic.

CAS 34642-77-8 Amoxicillin Sodium

Amoxicillin Sodium
(CAS: 34642-77-8)

Amoxicillin Sodium is a moderate- spectrum, bacteriolytic, β-lactam antibiotic.

CAS 3511-16-8 Hetacillin

Hetacillin
(CAS: 3511-16-8)

Hetacillin prepared from ampicillin and acetone is a penicillin beta-lactam antibiotic for the treatment of bacterial infections.

AFN-1252
(CAS: 620175-39-5)

AFN-1252 is an enoyl-(acyl-carrier protein) reductase fabl inhibitor, inhibited all clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis at...

PD 140248
(CAS: 147208-55-7)

PD 140248, a fluoronaphthyridine compound, has been found to have potential antibacterial effect especially against gram-positive pathogens. It has not been rep...

CAS 50370-12-2 Cefadroxil

Cefadroxil
(CAS: 50370-12-2)

Cefadroxilis a broad-spectrum antibiotic of the cephalosporin type as a first-generation cephalosporin antibiotic used to treat urinary tract infections

CAS 151213-16-0 BAY-Y 3118

BAY-Y 3118
(CAS: 151213-16-0)

BAY-Y 3118 is a 4-quinolone with outstanding antimicrobial activity against Gramnegative and Gram-positive pathogens as well as anaerobic and intracellular bact...

CAS 68401-82-1 Ceftizoxime sodium

Ceftizoxime sodium
(CAS: 68401-82-1)

A semisynthetic cephalosporin antibiotic for the treatment of infections due to susceptible strains of microorganisms.

CAS 15318-45-3 Thiamphenicol

Thiamphenicol
(CAS: 15318-45-3)

Thiamphenicol is an antimicrobial antibiotic and a methyl-sulfonyl analogue of chloramphenicol.

CP-5609
(CAS: 432038-96-5)

CP-5609 is a novel carbapenem with enhanced antimicrobial activities.

CAS 165800-04-4 Eperezolid

Eperezolid
(CAS: 165800-04-4)

Eperezolid(PNU-100592) is a oxazolidinone antibacterial agent, Eperezolid demonstrated good in vitro inhibitory activity, regardless of methicillin susceptibili...

Chemical Structure

CAS 873857-62-6 Fidaxomicin

Quick Inquiry

Verification code

Featured Items